Literature DB >> 15750336

Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product.

Yongjae Park1, Sunghoi Hong, Sung-Jo Kim, Seongman Kang.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal-dominant neurodegenerative disorder caused by expansion of the polyglutamine tract in the SCA1 gene product, ataxin-1. Using d2EGFP, a short-lived enhanced green fluorescent protein, we investigated whether polyglutamine-expanded ataxin-1 affects the function of the proteasome, a cellular multicatalytic protease that degrades most misfolded proteins and regulatory proteins. In Western blot analysis and immunofluorescence experiments, d2EGFP was less degraded in HEK 293T cells transfected with ataxin-1(82Q) than in cells transfected with lacZ or empty vector controls. To test whether the stability of the d2EGFP protein was due to aggregation of ataxin-1, we constructed a plasmid carrying ataxin-1-Delta114, lacking the self-association region (SAR), and examined degradation of the d2EGFP. Both the level of ataxin-1-Delta114 aggregates and the amount of d2EGFP were drastically reduced in cells containing ataxin-1-Delta114. Furthermore, d2EGFP localization experiments showed that polyglutamine-expanded ataxin-1 inhibited the general function of the proteasome activity. Taken together, these results demonstrate that polyglutamine-expanded ataxin-1 decreases the activity of the proteasome, implying that a disturbance in the ubiquitin-proteasome pathway is directly involved in the development of spinocerebellar ataxia type1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750336

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  15 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 2.  An update on inherited ataxias.

Authors:  Tanja Schmitz-Hübsch; Thomas Klockgether
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 3.  Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias.

Authors:  Antoni Matilla-Dueñas; Ivelisse Sánchez; Marc Corral-Juan; Antoni Dávalos; Ramiro Alvarez; Pilar Latorre
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

4.  Glial response to polyglutamine-mediated stress.

Authors:  Parminder J S Vig; Qingmei Shao; Maripar E Lopez
Journal:  Biosci Hypotheses       Date:  2009-01-01

5.  Abeta inhibits the proteasome and enhances amyloid and tau accumulation.

Authors:  Bertrand P Tseng; Kim N Green; Julie L Chan; Mathew Blurton-Jones; Frank M LaFerla
Journal:  Neurobiol Aging       Date:  2007-06-01       Impact factor: 4.673

6.  The Impact of MicroRNAs on Brain Aging and Neurodegeneration.

Authors:  Stephan P Persengiev; Ivanela I Kondova; Ronald E Bontrop
Journal:  Curr Gerontol Geriatr Res       Date:  2012-01-18

Review 7.  Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art.

Authors:  Matthew J Walsh; Johnathan Cooper-Knock; Jennifer E Dodd; Matthew J Stopford; Simeon R Mihaylov; Janine Kirby; Pamela J Shaw; Guillaume M Hautbergue
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

8.  Functional Annotation of Small Noncoding RNAs Target Genes Provides Evidence for a Deregulated Ubiquitin-Proteasome Pathway in Spinocerebellar Ataxia Type 1.

Authors:  Stephan Persengiev; Ivanela Kondova; Ronald E Bontrop
Journal:  J Nucleic Acids       Date:  2012-10-03

Review 9.  The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.

Authors:  Janet E Davies; Sovan Sarkar; David C Rubinsztein
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

10.  The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease.

Authors:  John S Bett; Casey Cook; Leonard Petrucelli; Gillian P Bates
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.